<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102596</url>
  </required_header>
  <id_info>
    <org_study_id>050092</org_study_id>
    <secondary_id>05-N-0092</secondary_id>
    <nct_id>NCT00102596</nct_id>
    <nct_alias>NCT01195909</nct_alias>
  </id_info>
  <brief_title>Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor</brief_title>
  <official_title>Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OVERVIEW

      Essential tremor (ET) is a common movement disorder affecting 0.4% of the general population
      and up to 14% of people 65 years and older. Response to medications such as beta blockers and
      primidone may be of benefit, but are often accompanied by intolerable side effects. Response
      to ethanol, on the other hand, has a roughly 80% chance of significant tremor reduction,
      though daily use of this as a treatment has potentially serious medical, social, and legal
      consequences.

      The leading hypothesis for ET pathophysiology is an unmasking of spontaneous oscillations
      originating in neurons of the inferior olive. Both ethanol and 1-octanol have been shown to
      reduce these spontaneous oscillations in an animal model of ET; however, 1-octanol does this
      at a dose much lower than that leading to intoxication, suggesting in may be useful in the
      treatment of essential tremor. Our initial studies with 1-octanol have shown it to be safe at
      dosages up to 64mg/kg without signs of intoxication, while at the same time showing benefit.

      OBJECTIVE

      We plan to evaluate the efficacy of different 1-octanol formulations in humans based on
      accelerometry and spirography. We will also evaluate drug and metabolite bioavailabilities
      using a high performance liquid chromatography (HPLC) detection method from plasma and urine
      samples.

      STUDY POPULATION

      We will study adult subjects with ethanol-responsive Essential Tremor (ET).

      DESIGN

      This study is designed as a two-phase unblinded inpatient study of adults with ET receiving
      weight-adjusted oral dosages of 2 different formulations of 1-octanol in a crossover fashion.
      Phase I of the study is designed to develop an octanol detection assay using HPLC. Four
      subjects will receive daily escalating dosages (1-32 mg/kg) of a single 1-octanol formulation
      followed by a crossover trial of both formulations at a dosage of 64 mg/kg. Phase II will
      study 20 subjects receiving one of the two formulations at 64 mg/kg on inpatient day 1
      followed by a 24 hour period of close monitoring. The second formulation will be given on day
      3 and the patient will again undergo close monitoring for 24 hours.

      OUTCOME MEASURES

      The primary outcome measures for the study will be efficacy based on tremor ratings from
      accelerometry and spirography. Secondary outcome measures will be the determination of
      bioavailability, pharmacodynamic and pharmacokinetic profiles of octanol #61864 and octanol
      #68751 and their metabolites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OVERVIEW

      Essential tremor (ET) is a common movement disorder affecting 0.4% of the general population
      and up to 14% of people 65 years and older. Response to medications such as beta blockers and
      primidone may be of benefit, but are often accompanied by intolerable side effects. Response
      to ethanol, on the other hand, has a roughly 80% chance of significant tremor reduction,
      though daily use of this as a treatment has potentially serious medical, social, and legal
      consequences.

      The leading hypothesis for ET pathophysiology is an unmasking of spontaneous oscillations
      originating in neurons of the inferior olive. Both ethanol and 1-octanol have been shown to
      reduce these spontaneous oscillations in an animal model of ET; however, 1-octanol does this
      at a dose much lower than that leading to intoxication, suggesting it may be useful in the
      treatment of essential tremor. Our initial studies with 1-octanol have shown it to be safe at
      dosages up to 64mg/kg without signs of intoxication, while at the same time showing benefit.

      OBJECTIVE

      We plan to evaluate the efficacy of different 1-octanol formulations in humans based on
      accelerometry and spirography. We will also evaluate drug and metabolite bioavailabilities
      using a high performance liquid chromatography (HPLC) detection method from plasma and urine
      samples.

      STUDY POPULATION

      We will study adult subjects with ethanol-responsive Essential Tremor (ET).

      DESIGN

      This study is designed as a two-phase unblinded inpatient study of adults with ET receiving
      weight-adjusted oral dosages of 2 different formulations of 1-octanol in a crossover fashion.
      Phase I of the study is designed to develop an octanol detection assay using HPLC. Four
      subjects will receive daily escalating dosages (1-32 mg/kg) of a single 1-octanol formulation
      followed by a crossover trial of both formulations at a dosage of 64 mg/kg. Phase II will
      study 20 subjects receiving one of the two formulations at 64 mg/kg on inpatient day 1
      followed by a 24 hour period of close monitoring. The second formulation will be given on day
      3 and the patient will again undergo close monitoring for 24 hours.

      OUTCOME MEASURES

      The primary outcome measures for the study will be efficacy based on tremor ratings from
      accelerometry and spirography. Secondary outcome measures will be the determination of
      bioavailability, pharmacodynamic and pharmacokinetic profiles of octanol #61864 and octanol
      #68751 and their metabolites.

      Addendum: Based on the results of the assays for all subjects who participated in Part 1 and
      2 of this protocol, we would like to conduct an exploratory study (Part 3) consisting of two
      subjects receiving a dose of 128mg/kg of 1-octanol. This is meant to primarily explore the
      plasma concentration of 1-octanol, while also providing valuable information regarding the
      safety and efficacy at this higher dose. The remainder of the experimental design will be
      maintained, with exception of additional safety precautions which will be discussed in the
      protocol and consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B</measure>
    <time_frame>0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose</time_frame>
    <description>Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Plasma Levels of Octanoic Acid After 64 mg/kg 1-Octanol Dose</measure>
    <time_frame>5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose</time_frame>
    <description>Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Post 1-Octanol Dose</measure>
    <time_frame>0 minutes, 15 minutes, 100 minutes and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR and QTc Intervals Post 1-Octanol Dose</measure>
    <time_frame>0 minutes, 15 minutes, 100 minutes and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Essential Tremor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1-Octanol</intervention_name>
    <description>1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients with alcohol-responsive Essential Tremor

          -  Limb involvement should be a prominent feature of the Essential tremor

          -  Patients must be willing and able to safely stop and remain off any medications used
             to treat essential tremor for at least 4 half-lives

          -  Patients must be willing to abstain from ethanol and caffeine intake for at least 48
             hours prior to starting the study hospitalization until study termination

          -  Patients must be willing and able to fast for periods of up to 12 hours during the
             study

        EXCLUSION CRITERIA:

          -  Patients with abnormalities other than tremor on neurological exam

          -  Patients with active or past alcohol abuse or dependence

          -  Patients with acute or chronic severe medical conditions such as renal failure,
             hepatic failure or lung disease

          -  Patients taking primidone

          -  Patients on other acute or chronic medications that influence hepatic metabolism or
             central nervous system (CNS) function and cannot be temporarily discontinued for the
             length of the study

          -  Patients who do not wish to take a potentially intoxicating drug

          -  Patients with abnormalities on their baseline screening laboratory tests

          -  Women who are pregnant or lactating

          -  Patients younger than age 21

          -  The presence of cognitive impairment preventing informed consent or cooperation during
             the study

          -  People of Far East Asian or Native American descent, who may possess variant alleles
             of the genes for alcohol metabolism, i.e., alcohol dehydrogenase and aldehyde
             dehydrogenase, resulting in altered (slower) metabolism and potentially increased
             sensitivity to alcohols and their metabolites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bikson M, Ghai RS, Baraban SC, Durand DM. Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity. J Neurophysiol. 1999 Nov;82(5):2262-70.</citation>
    <PMID>10561404</PMID>
  </reference>
  <reference>
    <citation>Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC. Is essential tremor benign? Neurology. 1991 Dec;41(12):1982-3.</citation>
    <PMID>1745359</PMID>
  </reference>
  <reference>
    <citation>Bushara KO, Goldstein SR, Grimes GJ Jr, Burstein AH, Hallett M. Pilot trial of 1-octanol in essential tremor. Neurology. 2004 Jan 13;62(1):122-4.</citation>
    <PMID>14718713</PMID>
  </reference>
  <reference>
    <citation>Fahn S, Tolosa E, Mar√≠n C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson's Disease and Movement Disorders. 2nd ed. Baltimore: Williams &amp; Wilkins; 1993. p. 225-34.</citation>
  </reference>
  <results_reference>
    <citation>Nahab FB, Wittevrongel L, Ippolito D, Toro C, Grimes GJ, Starling J, Potti G, Haubenberger D, Bowen D, Buchwald P, Dong C, Kalowitz D, Hallett M. An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics. 2011 Oct;8(4):753-62. doi: 10.1007/s13311-011-0045-1.</citation>
    <PMID>21594724</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2005</study_first_submitted>
  <study_first_submitted_qc>January 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2005</study_first_posted>
  <results_first_submitted>November 10, 2010</results_first_submitted>
  <results_first_submitted_qc>January 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2012</results_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ethanol</keyword>
  <keyword>Alcohol Responsive</keyword>
  <keyword>Movement Disorder</keyword>
  <keyword>Gas Chromatography</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Essential Tremor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A: Dose Escalation</title>
          <description>Subjects fasted overnight for 6 hours and received 1, 4, 8, 16, 32 and 64 mg/kg 1-octanol at 6AM on different days. There were 2 formulations:
1) 2 participants received 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; and 2) two participants received a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).</description>
        </group>
        <group group_id="P2">
          <title>Part B Then C: Fixed Dose</title>
          <description>In Part B, subjects fasted overnight for 6 hours and received 64 mg/kg 1-octanol at 6AM of both formulations:
1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
At the completion of Parts A and B, an exploratory Part C was added in which subjects fasted overnight for 6 hours and received 128 mg/kg 1-octanol at 6AM of both formulations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Assigned Treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failures</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants from Part A did not continue to Part B</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2">Only 2 patients participated in Part C</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Baseline is included for all participants who passed screening and received at least 1 dose of 1-octanol, whether in Part A, B or C</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of alcohol-responsive tremors</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of alcohol servings required for tremor response</title>
          <description>One serving of alcohol is 50 ml of 40% ethanol</description>
          <units>servings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of essential tremor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fahn Tolosa Marin Tremor Rating Scale</title>
          <description>Only available for the 10 participants who entered Part B. The Fahn Tolosa Marin Tremor Rating Scale was used. Minimum of this scale is 0, maximum is 164 points. Higher scores indicate more tremor. See Fahn S, Tolosa E, and Marin C (1993) &quot;Clinical rating scale for tremor&quot; reference provided in Protocol for full information.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B</title>
        <description>Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction.</description>
        <time_frame>0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose</time_frame>
        <population>All participants who received both formulations of 64 mg/kg 1-octanol in Part B</population>
        <group_list>
          <group group_id="O1">
            <title>64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 64 mg/kg of the 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages.</description>
          </group>
          <group group_id="O2">
            <title>64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 64 mg/kg of the 1-octanol in a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).</description>
          </group>
        </group_list>
        <measure>
          <title>Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B</title>
          <description>Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction.</description>
          <population>All participants who received both formulations of 64 mg/kg 1-octanol in Part B</population>
          <units>normalized score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normalized score at 0 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" spread="0.092"/>
                    <measurement group_id="O2" value="0.901" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.826" spread="0.104"/>
                    <measurement group_id="O2" value="0.738" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 60 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.786" spread="0.084"/>
                    <measurement group_id="O2" value="0.766" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 90 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.670" spread="0.082"/>
                    <measurement group_id="O2" value="0.685" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 120 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.662" spread="0.107"/>
                    <measurement group_id="O2" value="0.709" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 150 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.680" spread="0.101"/>
                    <measurement group_id="O2" value="0.746" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 180 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.645" spread="0.1"/>
                    <measurement group_id="O2" value="0.707" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 240 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.791" spread="0.129"/>
                    <measurement group_id="O2" value="0.683" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized score at 360 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.894" spread="0.223"/>
                    <measurement group_id="O2" value="0.122" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Plasma Levels of Octanoic Acid After 64 mg/kg 1-Octanol Dose</title>
        <description>Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose.</description>
        <time_frame>5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose</time_frame>
        <population>All participants who received either formulation 64 mg/kg 1-octanol in Part A or B</population>
        <group_list>
          <group group_id="O1">
            <title>64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 64 mg/kg of the 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages.</description>
          </group>
          <group group_id="O2">
            <title>64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 64 mg/kg of the 1-octanol in a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Plasma Levels of Octanoic Acid After 64 mg/kg 1-Octanol Dose</title>
          <description>Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose.</description>
          <population>All participants who received either formulation 64 mg/kg 1-octanol in Part A or B</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Octanoic Acid Level at 5 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.94" spread="29.37"/>
                    <measurement group_id="O2" value="74.16" spread="38.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 20 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5064.12" spread="4240.79"/>
                    <measurement group_id="O2" value="3885.52" spread="4111.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 45 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7967.97" spread="3078.81"/>
                    <measurement group_id="O2" value="9645.55" spread="5805.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 70 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6788.58" spread="2598.85"/>
                    <measurement group_id="O2" value="13315.26" spread="9162.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 100 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5701.60" spread="2207.62"/>
                    <measurement group_id="O2" value="9289.39" spread="2998.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 130 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5448.23" spread="1514.60"/>
                    <measurement group_id="O2" value="9605.68" spread="3822.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 160 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4662.88" spread="1719.10"/>
                    <measurement group_id="O2" value="6678.69" spread="2748.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 210 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3179.10" spread="1194.03"/>
                    <measurement group_id="O2" value="4307.74" spread="3135.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 270 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2248.74" spread="1192.60"/>
                    <measurement group_id="O2" value="2618.25" spread="2585.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Octanoic Acid Level at 360 min post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1266.37" spread="822.56"/>
                    <measurement group_id="O2" value="872.51" spread="758.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Post 1-Octanol Dose</title>
        <time_frame>0 minutes, 15 minutes, 100 minutes and 24 hours post-dose</time_frame>
        <population>All participants who received at least 1 dose of 1-octanol in Part A, B or C</population>
        <group_list>
          <group group_id="O1">
            <title>1-Octanol Dose</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 1-128 mg/kg of the 1-octanol</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Post 1-Octanol Dose</title>
          <population>All participants who received at least 1 dose of 1-octanol in Part A, B or C</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate at 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate at 100 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PR and QTc Intervals Post 1-Octanol Dose</title>
        <time_frame>0 minutes, 15 minutes, 100 minutes and 24 hours post-dose</time_frame>
        <population>All participants who received at least 1 dose of 1-octanol in Part A, B or C</population>
        <group_list>
          <group group_id="O1">
            <title>1-Octanol Dose</title>
            <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 1-128 mg/kg of 1-octanol</description>
          </group>
        </group_list>
        <measure>
          <title>PR and QTc Intervals Post 1-Octanol Dose</title>
          <population>All participants who received at least 1 dose of 1-octanol in Part A, B or C</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval at 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval at 100 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Interval at 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Interval at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Interval at 100 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Interval at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1-octanol Dose</title>
          <description>Subjects fasted overnight for 6 hours. At 6AM subjects received 1-128 mg/kg of 1-octanol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>due to flu</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>leading to fracture of one rib, accidental nature (patient slipped)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Taste Change</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gas/Bloating</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of tremor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fainting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment to study was ended early, as evidence became available, that a metabolite of the study substance promised significantly higher feasibility for treatment in ET.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Hallett, M.D.</name_or_title>
      <organization>NINDS/NIH</organization>
      <phone>301-496-9526</phone>
      <email>hallettm@ninds.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

